General Commentary
Published on 31 Jan 2020
Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
in Neuro-Oncology and Neurosurgical Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.00066
- 11,103 views
- 11 citations
